Second Product
Not Specified
CommercialApproved (FDA & EU 2025)
Key Facts
About Insmed
Insmed is a patient-centric, global biopharma leader with a mission to deliver transformative therapies for serious and rare diseases. The company has achieved significant commercial and clinical milestones, including regulatory approvals and advanced late-stage pipelines, underpinned by a culture consistently recognized as a top employer. Its strategy hinges on deep patient collaboration, a synergistic technology platform spanning drug delivery and small molecules, and a disciplined focus on high-need pulmonary and rare disease markets.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |